Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

QualiMed Innovative Medizinprodukte GmbH, Based in Winsen Germany has Received Notice of CE Approval for its Line of Peripheral



QualiMed Innovative Medizinprodukte GmbH, Based in Winsen Germany has Received
Notice of CE Approval for its Line of Peripheral Balloons for the Treatment of
                       Peripheral Vascular Obstructions

  PR Newswire

  HAMBURG, Germany, February 5, 2013

HAMBURG, Germany, February 5, 2013 /PRNewswire/ --

It is estimated that the global interventional peripheral device market will
exceed 4 Billion euros by 2015. The three largest portions of this market
ranked in order based on global market size are:

 1. Peripheral Vascular Stents which account for approximately 34% of the
    market
 2. PTA Balloon Catheters representing the 2 ^nd largest market segment
 3. Aortic Stent Graft claiming the third largest portions respectively.

The interventional peripheral market sector has been experiencing rapid growth
in technological advancements as well as significant consolidation over the
last 3 to 5 years. The mid cap consolidation is the primarily result of
acquisitions by large multinationals looking to establish an entry into the
peripheral markets, broaden their product portfolio, and expand their sales
reach and expertise in this area. Companies such as EV3 acquired by Covidien,
Invatec by Medtronic, Atrium by Marquette, Clear Stream by Bard, as well as a
number of others has left a void of peripheral vascular interventional
technology companies in the mid cap market. Further the consolidation of the
mid cap distribution channel into that of the acquirers has left an excess
channel capacity of well-trained distributors that have significant
relationship with existing clinicians, administrators, and support staff in
the geographies they represent.

Qualimed believes the availability of its current line of peripheral stents
coupled with its new line of innovative PTA Balloons in .035, .018, and .014
guide wire compatibility up to 280 mm lengths that minimize inflation and
deflation time as well as a line of AV Shunt balloons in .035 and .018 guider
compatibility with high pressure to 22 RBP allows the company to provide one
of the largest independent balloon production and product offerings globally.
This advanced balloon technology is available for sale through Qualimeds OEM,
Private Label, and Own Branded sales channels. This new offering, coupled with
the companies currently approved line of peripheral vascular stents,
aspiration devices, as well as future peripheral technologies that will be
launched in the 1 ^st half of 2013, uniquely position Qualimed to take
advantage of this channel opportunity and execute on its growth plans for in
the Asian-Pacific and Middle East regions.

Eric Mangiardi, Investor in Qualimed commented: "We are very pleased to
announce this significant milestone and to further execute on our strategy to
expand our product offering and technology advancements in the areas of
Interventional Cardiology, Peripheral Vascular, and Non-Vascular areas. This
new balloon technology will be the platform the company utilizes to complete
its illuminating balloon platform that allows visibility under x-ray without
the use of contrast media and its entrance into the drug eluting balloon
space."

QualiMed was founded in 1997 in Winsen, Germany near Hamburg, where it
develops, manufactures, and sells implantable medical devices in the
Cardiology, Peripheral Vascular, and Non Vascular areas. The innovations are
focused in the areas of Biodegradable Products, Drug Device Combination
Technologies, Catheter, and Mechanical implant areas. Originally founded as an
OEM, the company's products are now sold in over 50 countries worldwide
through its OEM, Private Label, and Own Brand Networks. The company and its
development partners have obtained CE and FDA approvals for more than 70
different products including 3 different drug eluting stents.

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including
development plans and objectives relating to the Group's products and
services), and any statements preceded by, followed by or that include
forward-looking terminology such as the words "targets", "believes",
"estimates", "expects", "aims", "intends", "will", "can", "may",
"anticipates", "would", "should", "could" or similar expressions or the
negative thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's control
that could cause the actual results, performance or achievements of the Group
to be materially different from future results, performance or achievements
expressed or implied by such forward-looking statements. Such forward-looking
statements are based on numerous assumptions regarding the Group´s present and
future business strategies and the environment in which the Group will operate
in the future. Among the important factors that could cause the Group's actual
results, performance or achievements to differ materially from those in
forward-looking statements include those relating to QualiMed's funding
requirements, regulatory approvals, clinical trials, reliance on third
parties, intellectual property, key personnel and other factors. These
forward-looking statements speak only as at the date of this announcement. The
Group expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Group's expectations with regard
thereto or any change in events, conditions or circumstances on which any such
statements are based. As a result of these factors, readers are cautioned not
to rely on any forward-looking statement.

For further information or product inquiries please contact:

QualiMed Innovative Medizinprodukte GmbH

Investor Relations Tel: +49(0)417165780 (main office) http://www.qualimed.de
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement